Back to search

Article

Secondary Analysis of Human Bulk RNA-seq Dataset Suggest Potential Mechanisms and Transcriptional Biomarkers for Letrozole Resistance in Estrogen Positive (ER+) Breast Cancer

2024-05-14

Abstract excerpt

Estrogen receptor-positive (ER+) breast cancer is common among postmenopausal women and is frequently treated with Letrozole. Letrozole inhibits aromatase from synthesizing estrogen from androgens. Decreased estrogen slows the growth of tumors and can be an effective treatment. Letrozole resistance is increasingly being observed, which poses a unique problem for patients. We reanalyzed transcriptomic data comparin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dab74c91-d6db-57ac-b16c-8ee1c8b36cdd
DOI
10.20944/preprints202405.0904.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Secondary Analysis of Human Bulk RNA-seq Dataset Suggest Potential Mechanisms and Transcriptional Biomarkers for Letrozole Resistance in Estrogen Positive (ER+) Breast CancerDOI 10.20944/preprints202405.0904.v1
An “Omics” Approach to Determine the Mechanisms of Acquired Aromatase Inhibitor ResistanceSemantic proximity
Investigation of the Genomic and Transcriptomic Variations Underlying Tamoxifen Resistance in Breast CancerSemantic proximity
Gene expression associated with endocrine therapy resistance in estrogen receptor-positive breast cancerSemantic proximity
Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to LetrozoleSemantic proximity
EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancerSemantic proximity
Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.Semantic proximity
Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity
Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity
Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer SubtypesSemantic proximity
RRM2 as a Key Biomarker and Therapeutic Target in Letrozole-Resistant ER+ Breast Cancer: Insights from Bioinformatics and Molecular DockingSemantic proximity
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.Semantic proximity
Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.